# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price targe...
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undia...
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.5...
https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...
-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and stati...
Leerink Partners analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Outperform rating and announces Pr...
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.